Pure Global
NCT06231745

Paroxetine Safety and Efficacy in Rheumatoid Arthritis

The GRK2 Inhibitor Paroxetine as a Novel Adjunct to Conventional Therapy in Rheumatoid Arthritis Patients.
Mostafa Bahaa·Phase 3·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Rheumatoid Arthritis
Drug/Device/Intervention
Methotrexate
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Mostafa Bahaa
Funder
Tanta University
Location
Damietta, Egypt
Timeline & enrollment
Phase
Phase 3
Start date
Jan 31, 2024
End date
Feb 20, 2026
Enrollment
100 participants
Primary outcome

The primary efficacy end point will be the change in the 28-joints disease activity score (DAS28).

Summary

Rheumatoid arthritis (RA) is a systemic chronic auto-inflammatory disorder which imposes a
 remarkable burden of morbidity and mortality on global health. The complex interaction
 between genetics, environment, and immunological response contribute to RA pathogenesis.
 Current treatment comprises conventional disease-modifying anti-rheumatic drugs (DMARDs)
 followed by biological DMARDs, if necessary, to achieve low disease activity or remission.
 Therapeutics used in RA had limitations in tolerability, access, and response duration and
 magnitude. Consequently, implementation of safe adjunctive treatment for RA is urgently
 needed to boost the therapeutic response.

ICD-10 classifications
Rheumatoid arthritis, unspecifiedOther rheumatoid arthritisOther specified rheumatoid arthritisRheumatoid arthritis with involvement of other organs and systemsSeronegative rheumatoid arthritis
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06231745
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06231745 through Pure Global AI's free database. This Phase 3 trial is sponsored by Mostafa Bahaa and is currently Recruiting. The study focuses on Rheumatoid Arthritis. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.